Figure 1. In vivo effect of fasting cycles in combination with chemotherapy on tumor glucose consumption and cancer growth.

CT26 cells were subcutaneously inoculated in the fat pad of BALB/c mice (200.000 cells/mouse). Five days after tumor cell inoculum, the mice were either fasted or maintained on the ad lib standard diet for 48 hours and treated with Oxaliplatin (OXP) (10 mg/Kg). After 1 week, the treatment was repeated. All mice were imaged after the first and the second cycle of therapy by a dedicated micro-PET system. Panel A shows the Patlak-map of a representative mouse for each group after the first cycle of treatment. Panel B shows the Patlak-map of a representative mouse for each group after the second cycle of treatment. Red arrows indicate the tumor mass. Panel C shows the cancer average glucose consumption expressed as nMol x min⁻¹ x gr⁻¹. Panel D shows the tumor volume expressed as mean value ± SD. Groups of experiments include: control (black), STS (green), OXP (light blue), and STS+OXP (red). Panel E shows the total cancer glucose consumption expressed as nMol x min⁻¹.